| 词条 | Atlas Venture |
| 释义 |
| logo = | name = Atlas Venture | type = Private | key_people = Kevin Bitterman Bruce Booth Jean-Francois Formela David Grayzel Jason Rhodes[1] | foundation = 1980 | founder = Michiel de Haan[2] | location = Cambridge, MA, United States | industry = Private Equity | products = venture capital funds | aum = $3 billion | num_employees = 15 | homepage = www.atlasventure.com| }}
HistoryAtlas has invested in over 150 life sciences startups since it began investing in the sector in 1990. Atlas invests in a range of therapeutic areas, including immuno-oncology, autoimmunity/inflammation, neuroscience, gene/cell therapy and editing, and anti-infectives. The current portfolio includes gene/cell editing/therapy companies AVROBIO, Generation Bio, Intellia Therapeutics, Obsidian Therapeutics, and Unum Therapeutics;[6] oncology companies Bicycle Therapeutics, Kyn Therapeutics, Replimune, Surface Oncology and Unum Therapeutics; autoimmunity companies Nimbus Therapeutics and Padlock Therapeutics; anti-infectives company Spero Therapeutics; synthetic biology company Synlogic; RNA companies miRagen Therapeutics and Translate Bio; and CNS companies Cadent Therapeutics, Disarm Therapeutics, Navitor, and Rodin Therapeutics; and novel platform companies Accent Therapeutics, Kymera Therapeutics,[7] Gemini Therapeutics, HotSpot Therapeutics, and Akero. Notable prior exits from Atlas’ life sciences portfolio include Actelion, Adnexus Therapeutics, Alnylam Pharmaceuticals, Annovation Biopharma, Annovation Biopharma, ArQule, Arrow Therapeutics, Arteaus Therapeutics, Avila Therapeutics, CoStim Pharmaceuticals, Crucell, deCODE genetics, Delinia, Exelixis, IFM Therapeutics Inc., Micromet, Momenta Pharmaceuticals, MorphoSys, Nimbus Apollo, Novexel, Padlock Therapeutics, Stromedix, and U3 Pharma.[8] Originally formed in 1980, Atlas historically invested in both life sciences and information technology startup companies. In October 2014, Atlas announced its shift to a biotech-only venture capital firm, with the technology-focused investment team forming a new firm, Accomplice, to continue investing in information technology startups.[9][10] Previously as a diversified firm, Atlas had raised over $3.0 billion of investor commitments across nine venture capital funds. The firm raised $705 million for its 2000-vintage fifth fund, $600 million for its 2001-vintage sixth fund, $385 million for its 2006-vintage seventh fund, $283 million for its 2009-vintage eighth fund, and $265 million for its 2013-vintage ninth fund.[11][12] At its largest, the firm held European offices in London, Paris and Munich,[13] and a West Coast office based in Seattle, Washington, in addition to the Boston-area headquarters. Today, the firm operates from a single office in Cambridge, Massachusetts. [14][15]In 2017, Atlas Venture announced it had raised $350 million in capital to invest in early stage biotech companies in the U.S. and around the world.[16] In January 2019 the company announced a fundraising with total value of $250 million.[17] References1. ^{{Cite web|url=https://atlasventure.com/team|title=Atlas Team - Atlas Venture|website=Atlas Venture|language=en-US|access-date=2016-03-15}} 2. ^{{Cite web|url=https://atlasventure.com/history|title=Atlas History - Atlas Venture|website=Atlas Venture|language=en-US|access-date=2017-10-25}} 3. ^Exclusive: Atlas Venture is splitting up. Fortune, October 2, 2014 4. ^Atlas rolls out its XI biotech fund, with $350M up for grabs. FierceBiotech, Jun 29, 2017 5. ^{{Cite web|url=http://medcitynews.com/2015/04/280m-fund-atlas-venture-focuses-exclusively-biotech/|title=With new $280M fund, Atlas Venture cuts the IT and "right-sizes" to biotech|last=Keshavan|first=Meghana|date=April 17, 2015|website=MedCityNews|publisher=|access-date=}} 6. ^{{Cite news|url=http://seekingalpha.com/news/3177875-intellia-therapeutics-deck-ipo|title=Intellia Therapeutics on deck for IPO|last=House|first=Douglas W.|date=29 April 2016|work=Seeking Alpha|access-date=1 May 2016|via=}} 7. ^{{Cite web|url=https://www.owler.com/company/kymeratx|title=Kymera Therapeutics Competitors, Revenue and Employees|last=|first=|date=|website=Owler Company Profile|publisher=Owler|at=Kymera Therapeutics Funding History|access-date=13 November 2018|quote=Series A funding, October 2017, $30 million, Atlas Venture one of three investors in round.}}{{dead link|date=November 2018|bot=medic}}{{cbignore|bot=medic}} 8. ^{{Cite web|url=https://atlasventure.com/portfolio|title=Portfolio - Atlas Venture|website=Atlas Venture|language=en-US|access-date=2016-03-15}} 9. ^{{Cite web|url=https://lifescivc.com/2014/10/atlas-venture-the-next-chapter/|title=Atlas Venture: The Next Chapter - LifeSciVC|last=|first=|date=October 2, 2014|website=Life Sci VC|publisher=|access-date=}} 10. ^{{Cite web|url=http://www.xconomy.com/boston/2015/06/29/fka-atlas-has-a-new-name-accomplice/|title=FKA Atlas Has a New Name: Accomplice|last=Huang|first=Gregory T.|date=June 29, 2015|website=Xconomy|publisher=|access-date=}} 11. ^Atlas Venture Closes New Fund with $283M, Does the Staffing Shuffle. XConomy, January 2009 12. ^Atlas Venture aims for new $500M fund {{Webarchive|url=https://web.archive.org/web/20121004093412/http://www.masshightech.com/stories/2008/11/03/daily31-Report-Atlas-Venture-aims-for-new-500M-fund.html |date=2012-10-04 }}. Mass High Tech, November 6, 2008 13. ^Changes in the Atlas Venture partnership. Fortune, April 8, 2014 14. ^[https://techcrunch.com/2010/01/19/atlas-venture-ups-sticks-to-boston/ Atlas Venture ups sticks to Boston]. Tech Crunch Europe, January 19, 2010 15. ^[https://dealbook.nytimes.com/2010/01/20/atlas-brings-its-european-ops-back-to-boston/ Atlas Brings Its European Ops Back to Boston]. New York Times DealBook, January 20, 2010 16. ^{{Cite news|url=http://www.xconomy.com/boston/2017/06/29/atlas-venture-unveils-new-350m-fund-for-seed-biotech-investments/|title=Atlas Venture Unveils New $350M Fund for Seed Biotech Investments {{!}} Xconomy|date=2017-06-29|work=Xconomy|access-date=2017-07-26|language=en-US}} 17. ^{{Cite web|url=https://techcrunch.com/2019/01/02/as-market-shifts-atlas-venture-closes-a-250-million-fund-to-support-its-breakaway-biotech-bets/|title=As market shifts, Atlas Venture closes a $250 million fund to support its breakaway biotech bets|website=TechCrunch|language=en-US|access-date=2019-01-03}} {{Venture capital firms}}{{Private equity and venture capital}} 4 : Private equity firms of the United States|Venture capital firms of the United States|Companies based in Boston|Companies established in 1980 |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。